J&J reports $100M in sales of COVID-19 vaccine

Health care giant Johnson & Johnson reported strong first-quarter numbers, boosted by sales of its one-dose COVID-19 vaccine — despite the shot currently being on pause in the United States.

J&J reported a first-quarter net income of $6.2 billion ($2.32 per share), which included $100 million from sales of the COVID-19 vaccine, according to the Associated Press. That is up 6.9 percent from $5.8 billion ($2.17 per share) from the same time last year.